Circadian Thermal Sensing to Detect Breast Disease

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine if Cyrcadia's Circadian Biometric Recorder (CBR™), which is attached to soft biometric patches worn on the body, can improve early breast cancer detection along with mammography or as a stand alone device.

Clinical Trial Description

The Cyrcadia CBR™ (Circadian Biometric Recorder) includes wearable biometric patches and a detachable data recording device. The CBR™ records chronobiologic data while the patient is totally ambulatory and going about her normal daily routine. Following removal of the detachable data recording device from the wearable biometric patches, the data is transferred to a computer for analysis. The Cyrcadia CBR™ will be placed on the patient for the duration of 2 to 24 hours. There is no restriction of daily activity. The study subject is requested to sponge bathe rather than shower while wearing the device, keeping the device dry during the testing procedure. After this period, the CBR™ will be removed and the data will be transferred to a computer for analysis.

The primary endpoint of this 173 patient study is to determine the accuracy of Cyrcadia CBR™ as a supplemental screening device to mammography and ultrasound in predicting a diagnosis of breast cancer. Specific emphasis will be on the utilization of the CBR as a secondary screening device to reduce the number of biopsies currently performed on non-cancerous tissue. A secondary emphasis will be on the CBR to act as an improved screening solution over mammography specifically in those patients with dense breast parenchymal tissue.

Other endpoints of the study are:

- to determine the accuracy of Cyrcadia CBR™, including the positive predictive value, negative predictive value, false negative rate and false positive rate.

- to determine the optimal wear time for the Cyrcadia CBR™.

- to demonstrate substantial equivalent or improved results when applied to Cyrcadia original patient case study with identical advanced neural network analysis computational results.

Study subjects will be followed at 6, 12, 18, and 24 months to update their clinical status. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02511301
Study type	Interventional
Source	Cyrcadia Health
Contact	Marie Norell, B.A., CCRA
Phone	775-233-1211
Email	manorell@cyrcadiahealth.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	June 2015
Completion date	February 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04290897` - Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors	Phase 2
Active, not recruiting	`NCT02592083` - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors	Phase 2
Active, not recruiting	`NCT02568839` - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer	Phase 2/Phase 3
Completed	`NCT02481128` - Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer	N/A
Active, not recruiting	`NCT03077841` - Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer	Phase 2/Phase 3
Completed	`NCT02310984` - PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional	N/A
Active, not recruiting	`NCT02474641` - Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer	N/A
Withdrawn	`NCT04560439` - Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors	N/A
Completed	`NCT02129686` - A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients	N/A
Completed	`NCT02806817` - ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism	Early Phase 1
Recruiting	`NCT02947425` - TARGeted Intraoperative radioTherapy (TARGIT) Registry Database
Active, not recruiting	`NCT02603679` - Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases	Phase 2
Active, not recruiting	`NCT03025139` - Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)	N/A
Completed	`NCT04081389` - Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer	Phase 1
Completed	`NCT02441946` - A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer	Phase 2
Completed	`NCT04294225` - Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.